Latest Lennox–Gastaut syndrome Stories
Looks to Expand Global Epilepsy Product Portfolio Tokyo, Sept 1, 2011 - (JCN Newswire) - Eisai Co., Ltd.
HATFIELD, England, Jan. 25, 2011 /PRNewswire/ -- Eisai announced today that it will submit Marketing Authorization Applications in the United States and the European Union for the investigational compound perampanel (E2007) based on the results of three Phase III pivotal studies.
HATFIELD, England, January 13, 2011 /PRNewswire-FirstCall/ -- - Epilepsy Treatment Zonegran(R) First Commercially Available Product Eisai Europe Limited, a subsidiary of Eisai Co., Ltd (Headquarters: Tokyo; President and CEO: Haruo Naito) announces the establishment of its sales and marketing operation in its wholly owned subsidiary in the Netherlands based in Amsterdam.
Harnessing the power of professional athletes, who wear helmets in their careers, to help erase the stigma associated with epilepsy. CHICAGO and NEW YORK, Nov. 2 /PRNewswire-USNewswire/ -- November is Epilepsy Awareness Month.
PRINCETON, N.J., March 27 /PRNewswire/ -- Zydus Pharmaceuticals announced today that it has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Topiramate Tablets USP, 25mg, 50mg, 100mg, and 200mg.
Ortho-McNeil Neurologics, a division of Ortho-McNeil-Janssen Pharmaceuticals, has announced that the FDA has granted pediatric exclusivity for Topomax.
TITUSVILLE, N.J., July 24 /PRNewswire/ -- Ortho-McNeil Neurologics, a division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., announced today that the U.S.